Publications by authors named "Elisa Biasco"

Claim this Profile
S
Sequencing radium 223 and other life-prolonging agents in castration-resistant prostate cancer patients.
Orazio Caffo, Viviana Frantellizzi, Fabio Monari, Andrea Sbrana, Renato Patrizio Costa, Elisa Biasco

Future Oncol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer patients sequentially treated with abiraterone acetate and RADIUM-223.
Orazio Caffo, Viviana Frantellizzi, Marcello Tucci, Luca Galli, Fabio Monari, Elisa Biasco

Eur J Nucl Med Mol Imaging· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of a treatment delay on outcome in metastatic renal cell carcinoma.
Roberto Iacovelli, Luca Galli, Ugo De Giorgi, Camillo Porta, Franco Nolè, Elisa Biasco

Urol Oncol· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer.
Orazio Caffo, Gaetano Facchini, Elisa Biasco, Francesco Ferraù, Franco Morelli

Future Oncol· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A case of a patient with severe renal failure on hemodialysis treated with vismodegib for relapsing basal cell carcinoma.
Andrea Sbrana, Andrea Antonuzzo, Luca Galli, Elisa Biasco, Gianna Musettini

Tumori· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma.
Roberto Iacovelli, Maria Cossu Rocca, Luca Galli, Roberto Sabbatini, Ugo De Giorgi, Elisa Biasco

Anticancer Drugs· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term Response to First-line Pazopanib Therapy in mRCC Patients: A Multicenter Italian Experience.
Andrea Sbrana, Elisa Biasco, Federico Paolieri, Erica Palesandro, Claudia Caserta

Anticancer Res· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacogenetics of androgen signaling in prostate cancer: Focus on castration resistance and predictive biomarkers of response to treatment.
Marzia Del Re, Stefania Crucitta, Giuliana Restante, Eleonora Rofi, Elena Arrigoni, Elisa Biasco

Crit Rev Oncol Hematol· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to Ugo De Giorgi, Vincenza Conteduca, and Emanuela Scarpi's Letter to the Editor re: Marzia Del Re, Elisa Biasco, Stefania Crucitta, et al. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. Eur Urol 2017;71:680-7.
Marzia Del Re, Elisa Biasco, Stefania Crucitta, Lisa Derosa, Eleonora Rofi

Eur Urol· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysis.
Daniele Santini, Raffaele Ratta, Francesco Pantano, Delia De Lisi, Marco Maruzzo, Elisa Biasco

Oncotarget· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer.
Roberto Iacovelli, Maria Cossu Rocca, Luca Galli, Ugo De Giorgi, Roberto Sabbatini, Elisa Biasco

Urol Oncol· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients.
Marzia Del Re, Elisa Biasco, Stefania Crucitta, Lisa Derosa, Eleonora Rofi

Eur Urol· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma.
Daniele Santini, Matteo Santoni, Alessandro Conti, Giuseppe Procopio, Elena Verzoni, Elisa Biasco

Oncotarget· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Small-bowel neuroendocrine tumor and retroperitoneal fibrosis: efficacy of octreotide and tamoxifen.
Elisa Biasco, Andrea Antonuzzo, Luca Galli, Giacomo Giulio Baldi, Lisa Derosa

Tumori· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients.
Lisa Derosa, Luca Galli, Paola Orlandi, Anna Fioravanti, Teresa Di Desidero, Elisa Biasco

Cancer· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early and prolonged response to pazopanib in a patient with multiple metastases from renal cell carcinoma: a case report.
Elisa Biasco, Andrea Antonuzzo, Claudia Cianci, Lisa Derosa, Riccardo Marconcini

Tumori· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis